Track topics on Twitter Track topics that are important to you
SAN DIEGO, CA--(Marketwired - August 04, 2016) - Medical Marijuana, Inc. (OTC: MJNA) announced today that the Company's Chief Executive Officer, Dr. Stuart Titus, was interviewed by the Uptick Network's Stock Day Radio Show about expanding access to cannabidiol (CBD)-based products to people across Latin America, recent developments for its pharmaceutical and biotechnology investment portfolio companies, and investing in the booming cannabis industry.
"Our mission is to change the way the world thinks about cannabis, which is why I'm always grateful when the news media gives us an opportunity to talk about the plethora of benefits that our products can produce and the advancements our company and the cannabis industry as a whole are making to change people's lives around the world," Dr. Titus said.
The interview with Dr. Titus, conducted by Uptick Newswire's CEO Everett Jolly, includes a discussion about the cannabis industry gaining ground in Latin America and how Medical Marijuana, Inc. plans to further expand into the region as demand for its products continue increasing. Dr. Titus also discusses how the Company's Real Scientific Hemp Oil-X™ (
became the first-ever cannabis product approved by federal authorities for import into Mexico.
Dr. Titus also gives an update on how investment portfolio company Kannalife Sciences, Inc. ("Kannalife") is creating intellectual property to treat diseases that affect the brain and the progress of investment portfolio company AXIM Biotechnologies'
first-ever human clinical trials into the dermatological use of CBD for psoriasis and atopic dermatitis. Dr. Titus concludes with a discussion on current investment opportunities in the cannabis market and how Medical Marijuana, Inc.'s diversified portfolio of cannabis companies and brands are capitalizing on the current cannabis revolution.
Dr. Titus will be speaking on Aug. 7 at 1 p.m. on "Cannabis and Medical Research," at the Southern California Cannabis Conference and Expo (SocalCCExpo) at the San Diego Convention Center and on Aug. 25 at 9:00 a.m. on cannabis investing and current global industry trends at The San Francisco Money Show's Cannabis Investing Symposium.
Visit here for the full Uptick Network interview with Dr. Titus.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...